Comera Life Sciences Holdings Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of its medical analysis and clinical research.
The company stated in the following press release that they use animals for product testing.
“SEQURUS-1 demonstrated no evidence of local or systemic toxicity of caffeine when administered subcutaneously with ipilimumab in animals. Furthermore, a rapid clearance of caffeine was seen within eight hours from test animals, in line with modeled predictions. Initial data also demonstrate no evidence of caffeine impact on ipilimumab absorption.” Read the following article
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. is headquartered in Woburn, Massachusetts.
Company Website: https://comeralifesciences.com